Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023

dc.contributor.authorPoukka, Eero
dc.contributor.authorPerälä, Jori
dc.contributor.authorNohynek, Hanna
dc.contributor.authorGoebeler, Sirkka
dc.contributor.authorAuranen, Kari
dc.contributor.authorLeino, Tuija
dc.contributor.authorBaum, Ulrike
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=tilastotiede|en=Statistics|
dc.contributor.organization-code1.2.246.10.2458963.20.42133013740
dc.converis.publication-id458373533
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/458373533
dc.date.accessioned2025-08-27T22:33:43Z
dc.date.available2025-08-27T22:33:43Z
dc.description.abstract<p><b>Background:</b> Long-term effectiveness data on bivalent COVID-19 boosters are limited.</p><p><b>Aim:</b> We evaluated the long-term protection of bivalent boosters against severe COVID-19 among >= 65-year-olds in Finland.</p><p><b>Methods:</b> In this register-based cohort analysis, we compared the risk of three severe COVID-19 outcomes among >= 65-year-olds who received a bivalent booster (Original/Omicron BA.1 or Original/BA.4-5; exposed group) between 1/9/2022 and 31/8/2023 to those who did not (unexposed). We included individuals vaccinated with at least two monovalent COVID-19 vaccine doses before 1/9/2022 and >= 3months ago. The analysis was divided into two periods: 1/9/2022-28/2/2023 (BA.5 and BQ.1.X predominating) and 1/3/2023- 31/8/2023 (XBB predominating). The hazards for the outcomes between exposed and unexposed individuals were compared with Cox regression.</p><p><b>Results:</b> We included 1,191,871 individuals. From 1/9/2022 to 28/2/2023, bivalent boosters were associated with a reduced risk of hospitalisation due to COVID19 (hazard ratio (HR):0.45; 95% confidence interval (CI):0.37-0.55), death due to COVID-19 (HR:0.49; 95%CI:0.38-0.62), and death in which COVID-19 was a contributing factor (HR:0.40; 95%CI:0.31-0.51) during 14-60days since vaccination. From 1/3/2023 to 31/8/2023, bivalent boosters were associated with lower risks of all three severe COVID-19 outcomes during 61-120days since a bivalent booster (e.g. HR:0.53; 95% CI: 0.39-0.71 for hospitalisation due to COVID-19); thereafter no notable risk reduction was observed. No difference was found between Original/Omicron BA.1 and Original/BA.4-5 boosters.</p><p><b>Conclusion:</b> Bivalent boosters initially reduced the risk of severe COVID-19 outcomes by ca 50% among >= 65-year-olds, but protection waned over time. These findings help guide vaccine development and vaccination programmes.</p>
dc.identifier.eissn1560-7917
dc.identifier.jour-issn1025-496X
dc.identifier.olddbid202380
dc.identifier.oldhandle10024/185407
dc.identifier.urihttps://www.utupub.fi/handle/11111/46933
dc.identifier.urlhttps://doi.org/10.2807/1560-7917.ES.2024.29.37.2300587
dc.identifier.urnURN:NBN:fi-fe2025082785701
dc.language.isoen
dc.okm.affiliatedauthorAuranen, Kari
dc.okm.affiliatedauthorDataimport, Kliinisen laitoksen yhteiset
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3142 Public health care science, environmental and occupational healthen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3142 Kansanterveystiede, ympäristö ja työterveysfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherEUR CENTRE DIS PREVENTION & CONTROL
dc.publisher.countrySwedenen_GB
dc.publisher.countryRuotsifi_FI
dc.publisher.country-codeSE
dc.publisher.placeSTOCKHOLM
dc.relation.articlenumber2300587
dc.relation.doi10.2807/1560-7917.ES.2024.29.37.2300587
dc.relation.ispartofjournalEurosurveillance
dc.relation.issue37
dc.relation.volume29
dc.source.identifierhttps://www.utupub.fi/handle/10024/185407
dc.titleRelative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
eurosurv-29-37-1.pdf
Size:
319.96 KB
Format:
Adobe Portable Document Format